Ftse Mib
34.731,31
0,00%
DAX
20.399,16
0,25%
S&P 500
6.084,19
0,82%
NASDAQ
20.034,89
1,77%
Bitcoin
100.566,71
-0,62%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Gyre Therapeutics Inc (GYRE) Gyre Therapeutics Inc (GYRE) Notizie

GYRE

Gyre Therapeutics (GYRE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GYRE
DataOraFonteTitoloSimboloCompagnia
27/11/202422:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GYREGyre Therapeutics Inc
27/11/202422:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GYREGyre Therapeutics Inc
25/11/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GYREGyre Therapeutics Inc
14/11/202422:39Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:GYREGyre Therapeutics Inc
13/11/202412:00GlobeNewswire Inc.Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
22/10/202422:05GlobeNewswire Inc.Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver FibrosisNASDAQ:GYREGyre Therapeutics Inc
01/10/202422:05GlobeNewswire Inc.Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor ConferenceNASDAQ:GYREGyre Therapeutics Inc
06/09/202414:31Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GYREGyre Therapeutics Inc
04/09/202422:05GlobeNewswire Inc.Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:GYREGyre Therapeutics Inc
13/08/202412:00GlobeNewswire Inc.Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
09/08/202413:00GlobeNewswire Inc.Gyre Therapeutics to Present at Sidoti Virtual Investor ConferenceNASDAQ:GYREGyre Therapeutics Inc
08/08/202422:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GYREGyre Therapeutics Inc
08/08/202422:05GlobeNewswire Inc.Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of DirectorsNASDAQ:GYREGyre Therapeutics Inc
02/07/202422:05GlobeNewswire Inc.Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ThrombocytopeniaNASDAQ:GYREGyre Therapeutics Inc
18/06/202422:05GlobeNewswire Inc.Gyre Therapeutics Announces Publication in Journal of Gastroenterology and HepatologyNASDAQ:GYREGyre Therapeutics Inc
30/05/202422:05GlobeNewswire Inc.Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial HypertensionNASDAQ:GYREGyre Therapeutics Inc
28/05/202422:05GlobeNewswire Inc.Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® IndexesNASDAQ:GYREGyre Therapeutics Inc
13/05/202422:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GYREGyre Therapeutics Inc
09/05/202422:10GlobeNewswire Inc.Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
26/03/202411:00GlobeNewswire Inc.Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:GYREGyre Therapeutics Inc
21/03/202412:00GlobeNewswire Inc.Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. NussbaumNASDAQ:GYREGyre Therapeutics Inc
15/12/202315:04PR Newswire (US)Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B FundingNASDAQ:GYREGyre Therapeutics Inc
13/11/202313:00GlobeNewswire Inc.Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver MeetingNASDAQ:GYREGyre Therapeutics Inc
01/11/202322:18Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GYREGyre Therapeutics Inc
01/11/202321:58Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:GYREGyre Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GYRE

La tua Cronologia

NASDAQ
IRWD
Ironwood Pharmaceuticals
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network